Comments on the chemotherapy of leprosy as influenced by present knowledge of Mycobacterium leprae.
D000814:Aniline Compounds / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D005000:Ethionamide / Q000627:therapeutic use; D006801:Humans; D007918:Leprosy / Q000188:drug therapy* / Q000276:immunology; D009166:Mycobacterium leprae / Q000187:drug effects; D010619:Phenazines / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D013828:Thioacetazone / Q000627:therapeutic use; D013882:Thiosemicarbazones / Q000627:therapeutic use; D013890:Thiourea / Q000627:therapeutic use
D000814:Aniline Compounds; D010619:Phenazines; D013449:Sulfonamides; D013450:Sulfones; D013882:Thiosemicarbazones; D003622:Dapsone; D013890:Thiourea; D013828:Thioacetazone; D005000:Ethionamide; D012293:Rifampin